#Clinical Trials — FinScans

Release 📈 Stocks

Translumina Initiates Global SPARX Trial for Drug-Coated Balloon Strategy

October 12, 2026 (12 days ago)

Translumina begins the multinational SPARX trial, testing a drug-coated balloon-first approach to improve patient outcomes in cardiovascular interventions.

Translumina

🌍 EUROPE Read More →

Release 📈 Stocks

Zydus Lifesciences Reports 60.7% PBC Treatment Response in U.S. Subgroup

October 12, 2026 (12 days ago)

Zydus Lifesciences shares gain momentum as Phase 3 EPICS-III trial data reveals superior biochemical response rates for saroglitazar in U.S. patients suffering…

ZYDUSLIFE

🌍 GLOBAL Read More →

Release 📈 Stocks

REGENXBIO Schedules Investor Event Ahead of 4Q 2026 Sura-vec Data Readout

October 12, 2026 (12 days ago)

REGENXBIO sets investor event to discuss the sura-vec wet AMD program, providing clinical updates and specialist perspectives ahead of the anticipated 4Q…

RGNX

🌍 AMERICAS Read More →

Release 📈 Stocks — 📊 Neutral

T-Maximum Pharmaceutical Receives FDA Clearance for Phase 2 MT027 CAR-T Trial

October 12, 2026 (12 days ago)

T-Maximum Pharmaceutical advances its oncology pipeline after receiving FDA clearance to initiate a Phase 2 clinical study for MT027, a B7-H3-targeted allogeneic…

🌍 ASIA Read More →

Release 📈 Stocks

Eli Lilly Shares Gain as TOGETHER-PsO Data Shows Zepbound Efficacy

October 9, 2026 (15 days ago)

Eli Lilly's latest clinical data reveals that the combination of Taltz and Zepbound drives significant biomarker improvements in psoriasis patients, reinforcing the…

LLY

🌍 AMERICAS Read More →

News 📈 Stocks

Anavex Life Sciences Shares Slip as Board Admits Incomplete Data Disclosures

October 8, 2026 (16 days ago)

Anavex Life Sciences faces potential volatility as the company warns investors to rely only on updated clinical trial data following admissions of…

AVXL

🌍 AMERICAS Read More →

Release 📈 Stocks — 📈 Bullish

Celltaxis Shares Rally as Clinical Data Validates LTA4H Inhibitor Efficacy

October 7, 2026 (17 days ago)

Positive clinical findings published in Scientific Reports provide independent validation for Celltaxis' therapeutic approach, driving short-term investor optimism regarding its LTA4H inhibitor…

🌍 GLOBAL Read More →

Release 📈 Stocks

InflammaSense Secures ARPA-H Funding for $38 Million CIRCLE Award Project

October 7, 2026 (17 days ago)

InflammaSense gains significant federal backing through the ARPA-H CIRCLE Award to advance its wearable sensor technology for critical care monitoring in a…

InflammaSense

🌍 AMERICAS Read More →

Release 📈 Stocks — 📊 Neutral

TranspireBio Completes Phase 1 Pharmacokinetic Study for Inhaled Therapeutics

October 6, 2026 (18 days ago)

TranspireBio Holdings Inc. advances its respiratory drug pipeline after successfully completing a pivotal Phase 1 pharmacokinetic study for its lead inhaled therapeutic…

🌍 AMERICAS Read More →

Release 📈 Stocks

Veeva Systems DQS Processes Data for Over 1 Million Clinical Subjects

October 6, 2026 (18 days ago)

Veeva Systems reports that its DQS platform has surpassed one million subjects processed, underscoring strong market adoption and the company's role in…

VEEV

🌍 AMERICAS Read More →

Release 📈 Stocks

Veeva Systems DQS Processes 1 Million Clinical Subjects Across 1,000 Studies

October 6, 2026 (18 days ago)

Veeva Systems reports its DQS platform has surpassed 1 million subjects processed, highlighting significant operational gains in clinical data management and cost…

VEEV

🌍 AMERICAS Read More →

Release 📈 Stocks

AnnJi Pharmaceutical Advances AJ201 to Phase 3 Trial for SBMA Treatment

October 6, 2026 (18 days ago)

AnnJi Pharmaceutical initiates Phase 3 testing for AJ201, the only clinical-stage oral therapy currently in development for spinal and bulbar muscular atrophy…

AnnJi Pharmaceutical

🌍 ASIA Read More →